Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company’s investigational product portfolio includes Oncophage® (vitespen), a patient-specific therapeutic cancer vaccine being evaluated in several indications; AroplatinÔ (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21 Stimulon, an adjuvant being evaluated by Antigenics’ corporate partners in several late-stage clinical trials. ( www.antigenics.com )
Antigenics , Inc.
162 Fifth Avenue Suite 900
New York, New York 10010
USA
Tel: (212) 994-8200
Fax: (212) 994-8299